Bone Mass in Patients with Familial Adenomatous Polyposis

Bone Mass in Patients with Familial Adenomatous Polyposis - BOMFAP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON32091

Enrollment

Registered

2008-07-17

Start date

2008-06-01

Completion date

Unknown

Last updated

2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high bone mass osteopetrosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Genetically and histologically documented diagnosis of FAP - Informed consent

Exclusion criteria

Exclusion criteria: - Use of bisphosphonates in the last 3 years - Current use of PTH (1-34 or 1-84)

Design outcomes

Primary

Measure	Time frame
The potential effect of genetic abnormalities in the APC gene on bone mineral density in patients with Familial Adenomatous Polyposis (FAP).	—

Secondary

Measure	Time frame
The potential effect of genetic abnormalities in the APC gene in FAP patients on - bone and mineral metabolism - prevalence of fractures - prevalence of joint disorders.	—

Countries

Netherlands

Outcome results